Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

397 - Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors; a comparative systematic review and Meta-analysis


20 Dec 2015


Poster presentation 2


Hesham Elhalawani


Annals of Oncology (2015) 26 (suppl_9): 37-39. 10.1093/annonc/mdv521


H. Elhalawani, O.M. Abdel-Rahman

Author affiliations

  • Clinical Oncology, Ain Shams University Hospital, 11361 - Cairo/EG


Abstract 397


We performed a systematic review and meta-analysis of the risk of gastrointestinal (GI) toxicities associated with MEK inhibitors.


Eligible studies included randomized phase II and III trials of cancer patients on the three MEK inhibitors (trametinib, selumetinib and cobimetinib); describing events of stomatitis, diarrhea and vomiting.


Our search strategy yielded 250 potentially relevant citations from Pubmed/Medline, Google scholar and CENTRAL Cochrane registry. After exclusion of ineligible studies, a total of 16 clinical trials were considered eligible for the meta-analysis. The relative risk (RR) of all-grade stomatitis, diarrhea and vomiting were 2.03 (95% CI 1.41-2.96; p = 0.002), 1.92(95% CI 1.48-2.50; p < 0.00001) and 1.35 (95% CI 1.06- 1.71; p = 0.01. Subgroup analyses according to agent used (trametinib vs. Selumetinib) and acccording to the cancer treated (melanoma vs. Non melanoma) did not reveal any significant difference between the subgroups.


Our meta-analysis has demonstrated that MEK inhibitor-based treatment is associated with an increased risk of stomatitis, diarrhea and vomiting compared to control. Clinicians should be aware of this risk and perform regular assessment.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings